A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer

Inhibition of epidermal growth factor receptor (EGFR) signalling contributes to the therapy of colorectal cancer. Gefitinib, an oral EGFR tyrosine kinase inhibitor, shows supra-additive growth inhibition with irinotecan and fluoropyrimidines in xenograft models. We designed a study to determine the...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Veronese, M L, Sun, W, Giantonio, B, Berlin, J, Shults, J, Davis, L, Haller, D G, O'Dwyer, P J
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2005
Témata:
Short Communication
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361767/
https://ncbi.nlm.nih.gov/pubmed/15870719
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602569
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky